Trial Catalyst Nears: Social media chatter highlights growing anticipation around Soleno Therapeutics' REGAL study, with traders noting the approach of a pivotal 80-event milestone in its acute myeloid leukemia program. Momentum appears to be building as recent price action reflects heightened expectations ahead of potential data.
Price Targets Discussed: Participants point to ambitious near-term price objectives circulating online, fueled by the stock's recent performance and elevated short interest. Discussions emphasize volatility risks tied to binary outcomes in the biotech space.
Note: This discussion summary was generated from an AI condensation of post data.
Soleno Therapeutics Hedge Fund Activity
We have seen 131 institutional investors add shares of Soleno Therapeutics stock to their portfolio, and 61 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- STATE STREET CORP added 4,600,202 shares (+54.8%) to their portfolio in Q2 2026, for an estimated $67,898,981
- ANSON FUNDS MANAGEMENT LP added 4,500,000 shares (+inf%) to their portfolio in Q2 2026, for an estimated $66,420,000
- BLACKROCK, INC. added 2,871,892 shares (+23.5%) to their portfolio in Q2 2026, for an estimated $42,389,125
- MARSHALL WACE, LLP removed 2,037,162 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $30,068,511
- SUSQUEHANNA INTERNATIONAL GROUP, LLP added 1,653,541 shares (+416.5%) to their portfolio in Q2 2026, for an estimated $24,406,265
- BNP PARIBAS FINANCIAL MARKETS added 1,025,006 shares (+2180.1%) to their portfolio in Q2 2026, for an estimated $15,129,088
- GEODE CAPITAL MANAGEMENT, LLC added 971,569 shares (+24.8%) to their portfolio in Q2 2026, for an estimated $14,340,358
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
